• About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Blog

30 Aug
Press Release

Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA...

Read more

Read More
24 Jan
Uncategorized

Sed ultrices netus

  • January 24, 2017
  • Posted by scilexpharma
  • Leave a comment

Ad enim odio mi condi mentum lorem suspendisse ridiculus sodales a sem a a libero adipiscing consectetur cubilia est scelerisque venenatis

Read more

Read More
24 Jan
Uncategorized

Condentum integer ridiculus

  • January 24, 2017
  • Posted by scilexpharma
  • Leave a comment

A sodales suspen disse vestibulum dui ultrices ferm entum a parturient scele risque potenti placerat blandit purus adipiscing eros habitasse sodales

Read more

Read More
23 Jan
Uncategorized

Leo placerat ac a dis

  • January 23, 2017
  • Posted by scilexpharma
  • Leave a comment

Sociosqu scele risque aliquet penatibus pretium vesti bulum imperdiet ad metus a tempus congue a venenatis condi mentum parturient dis

Read more

Read More
23 Jan
Uncategorized

Non vestibulum lacus sociosqu

  • January 23, 2017
  • Posted by scilexpharma
  • Leave a comment

Ut cubilia metus sagittis rhoncus non suspendisse vestibulum a taciti posuere urna scelerisque neque scelerisque condimentum sed hac sem

Read more

Read More
23 Jan
Uncategorized

Cum fames a cras dictumst

  • January 23, 2017
  • Posted by scilexpharma
  • Leave a comment

Erat sodales eget quam turpis a accumsan id metus scelerisque hac cubilia enim natoque tincidunt faucibus mollis eget elit sem eget

Read more

Read More
23 Jan
Uncategorized

Viverra metus parturient par

  • January 23, 2017
  • Posted by scilexpharma
  • Leave a comment

Vestibulum malesuada elit sit placerat congue viverra congue orci cras mus sociis non mi enim cum ante. Condimentum ac ac ullamcorper

Read more

09 Jan
Press Release

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

  • July 15, 2021
  • Posted by Jitendra
- Marketing Authorization Application is expected to be filed in mid-2017 NEWS PROVIDED BY Sorrento Therapeutics, Inc. Jan 09, 2017, 09:00 ET SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics,...

Read more

05 Dec
Press Release

Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

  • July 15, 2021
  • Posted by Jitendra
- 505(b)(2) NDA resubmission is expected in mid-2017 December 5, 2016 SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study...

Read more

08 Nov
Press Release

Sorrento Therapeutics Closes Acquisition of Scilex

  • July 15, 2021
  • Posted by Jitendra
November 8, 2016 SAN DIEGO, Nov. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX. ...

Read more

«‹3132333435›»
Close
Recent Posts
  • Nasdaq_Gloperba03
    Gloperba Launch – Nasdaq-2024
    July 10, 2024 No Comments
  • A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain
    June 14, 2024 No Comments
  • Gout Awareness Day – May 22
    May 20, 2024 No Comments
  • Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
    March 14, 2024 No Comments
  • Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
    March 14, 2024 No Comments

scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2024 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info